REVIVE THERAPEUTICS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.025 CAD | 0.00% |
|
-16.67% | -16.67% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Companyâs cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.
Calendar
2024-05-26
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -16.67% | 7.58M | |
| -3.39% | 102B | |
| +2.61% | 96.84B | |
| -0.70% | 21.48B | |
| -18.14% | 20.82B | |
| -7.49% | 18.6B | |
| -40.70% | 16.81B | |
| -26.89% | 13.78B | |
| +1.12% | 13.4B | |
| +22.25% | 11.06B |
- Stock Market
- Equities
- RVV Stock
- News Revive Therapeutics Ltd.
- Revive Therapeutics Falls 17% as Making Private Placement Offering of Up To $5 Million
